GlycoVaxyn AG

GlycoVaxyn AG is a Swiss vaccine-technology company associated with the development of a proprietary E. coli-based platform for producing complex carbohydrate and protein vaccine candidates. The company's scientific focus was on engineering bacterial hosts to generate glycoconjugate antigens in a single, scalable process, an approach intended to simplify and accelerate the development of vaccines against infectious diseases. The technology and expertise associated with GlycoVaxyn are now represented by LimmaTech Biologics AG, whose official website describes a proprietary multivalent vaccine platform built on decades of experience in engineering E. coli to create complex carbohydrate and protein molecules. LimmaTech states that it is using this platform, alongside additional disease-specific approaches, to develop vaccines against antimicrobial-resistant pathogens. Because the available evidence for this entry consists primarily of LimmaTech Biologics' current corporate and technology pages, the dossier treats GlycoVaxyn AG as the historical Swiss vaccine-technology entity whose platform and team are continued within LimmaTech. Details such as the exact founding year, original headquarters, founders, and ownership history are not established by the supplied evidence and are therefore left unspecified.

GlycoVaxyn AG is a Swiss vaccine-technology company whose work centered on a proprietary platform for producing glycoconjugate vaccine candidates in engineered E. coli. The approach was designed to enable the creation of complex carbohydrate and protein molecules that can serve as vaccine antigens, with the aim of simplifying production and accelerating development timelines. The technology associated with GlycoVaxyn is now described by LimmaTech Biologics AG, which presents itself as having pioneered vaccine development technologies and as leveraging decades of experience in engineering E. coli to create complex carbohydrate and protein molecules. LimmaTech's proprietary multivalent vaccine platform is described as enabling vaccine candidates that contain multiple immunogenic antigens and can be produced in a single, scalable step. A key aspect of the platform is the engineering of an E. coli strain to also produce self-adjuvanting vaccine candidates, which is intended to maximize potency and provide lasting protection. LimmaTech states that it is using this platform, alongside additional disease-specific vaccine approaches, to develop vaccines against antimicrobial-resistant pathogens. The company describes its mission as preventing infections before they take hold and averting disease manifestation, positioning vaccines as a vital part of the strategy to fight antimicrobial resistance. Because the supplied evidence does not include dated corporate events for GlycoVaxyn AG itself, this history remains a technology-and-continuity narrative rather than a chronological corporate record. Specific milestones such as founding, financing rounds, partnerships, or acquisitions are not established by the available sources and are therefore not asserted here.

Vaccine-technology company focused on complex carbohydrate and protein antigens produced in engineered E. coli.

• Proprietary multivalent vaccine technology platform

  A platform enabling vaccine candidates that contain multiple immunogenic antigens and can be produced in a single, scalable step using engineered E. coli.

• Self-adjuvanting vaccine candidates

  Vaccine candidates produced by an engineered E. coli strain that also acts as an adjuvant, intended to maximize potency and provide lasting protection.

1. 1LimmaTech Biologics AG | Homelmtbio.com
2. 2Company | LimmaTech Biologics AGlmtbio.com
3. 3Proprietary Vaccine Platform | LimmaTech Biologics AGlmtbio.com
4. 4GlycoVaxyn AGwikidata.org